Vectorite Biomedical Profit Margin

Vectorite Biomedical (4170.TWO) currently reports a profit margin of 77.42% as of June 2026. That compares with -28.23% in the prior-year period — up 374.3% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore Vectorite Biomedical's profit margin history and peer comparisons.

Vectorite Biomedical's profit margin increased from -28.23% to 77.42% — a 374.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vectorite Biomedical's profit margin of 77.42% is higher than the Healthcare sector average of 21.34%. That is roughly 262.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Vectorite Biomedical's current 77.42% should be judged against Healthcare norms (sector average: 21.34%) and against 4170.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 77.42%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Vectorite Biomedical, and consider following 4170.TWO for alerts when major investors trade the stock.